Abstract
Abstract Aim: To analyze the clinicopathologic characteristics, prognostic factors, and treatment of gastrointestinal stromal tumors (GISTs). Methods: We conducted a retrospective analysis of all cases of GISTs treated in the Medical Oncology Unit from 2010 through 2015. Results: We analyzed 44 patients with a median age of 49.43 years (17-76 years) with sex ratio 1:1. The main symptom was abdominal pain. Thirty patients had limited-stage disease and 14 patients had metastatic disease. We observed 90% of the immunohistochemistry exams were positive for CD117 (c-Kit+). The most frequent location was in the stomach (45%), the high-risk group was predominant (50%) and the average tumor size is 12.84 cm. Surgery was considered R0 (extensive) in 75% of the cases and the main sites of metastases were liver and peritoneum.25 patients received imatinib 400 mg qDay in adjuvant setting,5 patients in neoadjuvant, 13 patients in palliative and 1 patient had best supportive care. A total of 44 patients were followed up for 1 to 78 months.6 patients (13 %) developed recurrence or metastasis during or after adjuvant treatment. Two patients had surgery after neoadjuvant treatment(40%). 4 patients treated in second line with imatinib 800 mg qDay, 5 patients with sunitinib and 2 patients rechallenged in third line with imatinib 800 mg qDay. Conclusion: Our patients presented mainly in the form of high-risk disease, Surgery is the mainstay treatment when GISTs are localized, Adjuvant therapy is used depending their risk of relapse. In the advanced disease, tyrosine kinase inhibitors have substantially improved the prognosis of GISTs. Note: This abstract was not presented at the meeting. Citation Format: Soufyane Ali Boukhalfa, Tah Filali. Gastrointestinal stromal tumor: Retrospective analysis of 44 cases of center of reference in eastern Algeria [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4232. doi:10.1158/1538-7445.AM2017-4232
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
